Lenvatinib
Lenvatinib is a tyrosine kinase inhibitor that targets multiple receptors involved in angiogenesis and tumor growth. It is indicated for the treatment of certain types of cancer. Lenvatinib is anticancer drug which is multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.Lenvatinib is indicated for the treatment of: -Differentiated thyroid cancer (DTC) that is refractory to radioactive iodine. -Unresectable hepatocellular carcinoma (HCC). -locally recurrent or metastatic, progressive, radioactive iodine-refractory Differentiated Thyroid Carcinoma, in combination with everolimus for the treatment of patients with advanced Renal cell carcinoma following one prior anti-angiogenic therapy.
-The dosage of Lenvatinib may vary depending on the specific indication and individual patient factors. It is crucial to follow the prescribing physician's instructions. Typically, Lenvatinib is administered orally once daily. -Oral; 14-28 mg daily dose modification to be done according to grade of carcinoma.
Lenvatinib is contraindicated in individuals with known hypersensitivity to the drug. It should not be used in patients with severe hepatic impairment.
-Hepatic Impairment: Use with caution in patients with mild to moderate hepatic impairment. Avoid in severe hepatic impairment. -Cardiac Events: Monitor for cardiac events, especially in patients with a history of cardiac disease. -Hypertension: Monitor blood pressure regularly and manage hypertension appropriately. -Proteinuria: Monitor for proteinuria and manage accordingly. -Wound Healing Complications: Discontinue treatment prior to surgery to reduce the risk of wound healing complications. Paediatric: safety and effectiveness in pediatric patients have not been established. Pregnancy: No human data available. It has teratogenic effect in animal studies. Lactation: advise women to discontinue breastfeeding during treatment. Elderly: No difference in safety and efficacy was found in young and elderly people.
-Common side effects of Lenvatinib may include hypertension, fatigue, diarrhea, decreased appetite, and nausea. Serious side effects may include cardiac events, hepatotoxicity, and gastrointestinal perforation. It is important to report any adverse reactions to the healthcare provider promptly. -Hypertension, Cardiac Dysfunction, Arterial Thromboembolic Events, Hepatotoxicity , Proteinuria , Diarrhea, Renal Failure and Impairment, diarrhea, fatigue, Gastrointestinal Perforation and Fistula Formation, QT Interval Prolongation, Hypocalcemia, Reversible Posterior Leukoencephalopathy Syndrome, Hemorrhagic Events, Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction, Wound Healing Complications.
-Strong CYP3A4 Inhibitors: Concomitant use may increase Lenvatinib concentrations. Adjust the dosage as necessary. -Strong CYP3A4 Inducers: Avoid concomitant use as it may reduce Lenvatinib concentrations. -Anticoagulants: Increased risk of bleeding with concurrent use.
